Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients. The company offers enoxaparin, a low molecular weight heparin that is used as an anticoagulant for the prevention and treatment of deep vein thrombosis; naloxone for opioid overdose; Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; and lidocaine jelly, a local anesthetic product for urological procedures. It also provides lidocaine topical solution for various procedures; phytonadione injection for newborn babies; syringe products, such as morphine, atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate for emergency use in hospital settings; lorazepam injection for surgery and medical procedures; ketorolac for acute pain management; procainamide for documented ventricular arrhythmias; medroxyprogesterone acetate injectable suspension for the prevention of pregnancy. In addition, the company manufactures and distributes recombinant human and porcine insulins. Further, it develops Primatene Mist, an over-the-counter epinephrine inhalation product candidate for the temporary relief of mild symptoms of intermittent asthma. Additionally, the company has a pipeline of 20 generic and proprietary product candidates in various stages of development for various indications. Its products are used in hospital or urgent care clinical settings, and primarily contracted and distributed through group purchasing organizations and drug wholesalers. Amphastar Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AMPH
CUSIPN/A
Phone909-980-9484
Debt
Debt-to-Equity Ratio0.12
Current Ratio2.40
Quick Ratio1.53
Price-To-Earnings
Trailing P/E Ratio42.37
Forward P/E Ratio53.67
P/E Growth2.53
Sales & Book Value
Annual Sales$240.18 million
Price / Sales3.12
Cash Flow$0.6943 per share
Price / Cash23.19
Book Value$7.34 per share
Price / Book2.19
Profitability
EPS (Most Recent Fiscal Year)$0.38
Net Income$4.50 million
Net Margins-1.50%
Return on Equity3.39%
Return on Assets2.52%
Miscellaneous
Employees1,644
Outstanding Shares46,610,000
Amphastar Pharmaceuticals (NASDAQ:AMPH) Frequently Asked Questions
What is Amphastar Pharmaceuticals' stock symbol?
Amphastar Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMPH."
How will Amphastar Pharmaceuticals' stock buyback program work?
Amphastar Pharmaceuticals announced that its Board of Directors has approved a stock repurchase plan on Thursday, August 10th 2017, which allows the company to buyback $20,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to reacquire up to 2.8% of its stock through open market purchases. Stock buyback plans are often an indication that the company's board of directors believes its shares are undervalued.
How were Amphastar Pharmaceuticals' earnings last quarter?
Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) announced its quarterly earnings data on Wednesday, May, 9th. The company reported ($0.05) earnings per share for the quarter, missing analysts' consensus estimates of $0.08 by $0.13. The firm earned $58.40 million during the quarter, compared to the consensus estimate of $60.75 million. Amphastar Pharmaceuticals had a negative net margin of 1.50% and a positive return on equity of 3.39%. The company's revenue for the quarter was up 3.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.09 EPS. View Amphastar Pharmaceuticals' Earnings History.
What price target have analysts set for AMPH?
6 equities research analysts have issued 1-year price targets for Amphastar Pharmaceuticals' stock. Their forecasts range from $18.00 to $26.00. On average, they anticipate Amphastar Pharmaceuticals' stock price to reach $21.20 in the next twelve months. View Analyst Ratings for Amphastar Pharmaceuticals.
Who are some of Amphastar Pharmaceuticals' key competitors?
Some companies that are related to Amphastar Pharmaceuticals include Blueprint Medicines (BPMC), Horizon Pharma (HZNP), Supernus Pharmaceuticals (SUPN), Portola Pharmaceuticals (PTLA), Ironwood Pharmaceuticals (IRWD), Ascendis Pharma A/S (ASND), The Medicines (MDCO), Emergent Biosolutions (EBS), Evotec (EVTCY), Intercept Pharmaceuticals (ICPT), Arena Pharmaceuticals (ARNA), OPKO Health (OPK), Clovis Oncology (CLVS), Akcea Therapeutics (AKCA) and Xencor (XNCR).
Who are Amphastar Pharmaceuticals' key executives?
Amphastar Pharmaceuticals' management team includes the folowing people:
- Dr. Ziping Luo, Chairman, Chief Scientist & COO (Age 68)
- Dr. Yongfeng Zhang, CEO, Chief Science Officer & Director (Age 71)
- Mr. Jason B. Shandell, Pres & Director (Age 44)
- Mr. William J. Peters, CFO, Treasurer & Sr. VP of Fin. (Age 50)
- Mr. Rong Zhou, Exec. VP of Production Center (Age 59)
Has Amphastar Pharmaceuticals been receiving favorable news coverage?
News headlines about AMPH stock have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Amphastar Pharmaceuticals earned a daily sentiment score of 0.04 on Accern's scale. They also assigned media headlines about the company an impact score of 45.51 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
Who are Amphastar Pharmaceuticals' major shareholders?
Amphastar Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (11.59%), Dimensional Fund Advisors LP (3.62%), Rothschild Asset Management Inc. (0.68%), JPMorgan Chase & Co. (0.63%), Principal Financial Group Inc. (0.59%) and Principal Financial Group Inc. (0.59%). Company insiders that own Amphastar Pharmaceuticals stock include Diane G Gerst, Floyd F Petersen, Howard Lee, Jack Y Zhang, Jason B Shandell, Michael A Zasloff, Richard K Prins, Rong Zhou, Stephen B Shohet and William J Peters. View Institutional Ownership Trends for Amphastar Pharmaceuticals.
Which major investors are selling Amphastar Pharmaceuticals stock?
AMPH stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, JPMorgan Chase & Co., BlackRock Inc., Citigroup Inc., Point72 Asset Management L.P., Fisher Asset Management LLC, Russell Investments Group Ltd. and Rothschild Asset Management Inc.. Company insiders that have sold Amphastar Pharmaceuticals company stock in the last year include Diane G Gerst, Floyd F Petersen, Jason B Shandell, Michael A Zasloff, Richard K Prins, Stephen B Shohet and William J Peters. View Insider Buying and Selling for Amphastar Pharmaceuticals.
Which major investors are buying Amphastar Pharmaceuticals stock?
AMPH stock was purchased by a variety of institutional investors in the last quarter, including Cortina Asset Management LLC, Mackay Shields LLC, Dimensional Fund Advisors LP, Matarin Capital Management LLC, Citadel Advisors LLC, Campbell & CO Investment Adviser LLC, A.R.T. Advisors LLC and Wells Fargo & Company MN. View Insider Buying and Selling for Amphastar Pharmaceuticals.
How do I buy shares of Amphastar Pharmaceuticals?
Shares of AMPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Amphastar Pharmaceuticals' stock price today?
One share of AMPH stock can currently be purchased for approximately $16.10.
How big of a company is Amphastar Pharmaceuticals?
Amphastar Pharmaceuticals has a market capitalization of $790.57 million and generates $240.18 million in revenue each year. The company earns $4.50 million in net income (profit) each year or $0.38 on an earnings per share basis. Amphastar Pharmaceuticals employs 1,644 workers across the globe.
How can I contact Amphastar Pharmaceuticals?
Amphastar Pharmaceuticals' mailing address is 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730. The company can be reached via phone at 909-980-9484 or via email at [email protected]
MarketBeat Community Rating for Amphastar Pharmaceuticals (AMPH)
MarketBeat's community ratings are surveys of what our community members think about Amphastar Pharmaceuticals and other stocks. Vote "Outperform" if you believe AMPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
